Rising Rheumatoid Arthritis Cases Driving The Market Growth Continues To Impact The Growth Of The Arthralgia Market

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Expected Market Value Outlook For The Arthralgia Market Through 2030?

The arthralgia market has experienced substantial growth in recent years. This market is projected to expand from $5.62 billion in 2025 to $6.09 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.2%. The historical increase can be attributed to the rising occurrence of joint-related disorders, an aging demographic, heightened awareness of musculoskeletal health, the expanding range of pharmaceutical pain management options, and the growth in outpatient orthopedic care.

The arthralgia market is projected to experience substantial expansion in the coming years. It is anticipated to reach $8.26 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.9%. This expansion throughout the forecast period can be attributed to several factors, including a heightened demand for customized treatment plans, an increase in the use of biologic and targeted treatments, the broader availability of home-based options for pain relief, a stronger emphasis on managing symptoms over an extended duration, and increased funding for research into joint health. Key trends expected during this period involve a greater acceptance of individualized pain management strategies, an uptick in the utilization of combined treatment methods, an intensified focus on identifying joint disorders early, the proliferation of non-invasive options for pain alleviation, and improved models for patient-focused care.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21104&type=smp

Which Strategic Drivers Are Supporting The Arthralgia Market Development?

The increasing prevalence of rheumatoid arthritis is projected to drive the expansion of the arthralgia market. Rheumatoid arthritis, a chronic autoimmune condition primarily affecting joints, leads to inflammation, pain, and potential joint damage. The rise in rheumatoid arthritis cases is linked to factors like aging populations, genetic predispositions, shifts in lifestyle, and environmental elements such as smoking and pollution. This condition triggers arthralgia through chronic joint inflammation, causing pain, stiffness, and progressive deterioration. For illustration, data from Arthritis Australia, an Australia-based non-profit organization, in February 2024, indicates that arthritis cases in Australia are expected to increase to 5.39 million by 2040 from 4.11 million in 2025. Within this, osteoarthritis is predicted to grow to 3.11 million from 2.35 million, and rheumatoid arthritis cases are anticipated to reach 748,721. Hence, the escalating number of rheumatoid arthritis cases is a significant driver for the growth of the arthralgia market.

Which Segment Groups Define The Arthralgia Market Landscape?

The arthralgia market covered in this report is segmented –

1) By Cause: Osteoarthritis, Rheumatoid Arthritis, Gout, Psoriatic Arthritis, Lupus, Injuries, Infections, Other Causes

2) By Treatment Type: Medications, Therapies, Surgical Interventions, Lifestyle And Home Remedies

3) By Route Of Administration: Oral, Injectable, Topical, Transdermal

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By End User: Hospital, Clinics, Homecare Settings, Rehabilitation Centers

Subsegments:

1) By Osteoarthritis: Knee Osteoarthritis, Hip Osteoarthritis, Hand Osteoarthritis, Spine Osteoarthritis, Shoulder Osteoarthritis

2) By Rheumatoid Arthritis: Seropositive Rheumatoid Arthritis, Seronegative Rheumatoid Arthritis, Juvenile Rheumatoid Arthritis, Early-Onset Rheumatoid Arthritis

3) By Gout: Primary Gout, Secondary Gout, Gouty Arthritis

4) By Psoriatic Arthritis: Symmetric Psoriatic Arthritis, Asymmetric Psoriatic Arthritis, Psoriatic Spondylitis, Distal Interphalangeal Predominant Psoriatic Arthritis

5) By Lupus: Systemic Lupus Erythematosus (SLE), Discoid Lupus Erythematosus, Drug-induced Lupus, Neonatal Lupus

6) By Injuries: Sports-related Injuries, Trauma and Fractures, Sprains and Strains, Tendon or Ligament Damage

7) By Infections: Septic Arthritis, Viral Arthritis, Bacterial Infections, Fungal Infections

8) By Other Causes: Fibromyalgia, Overuse Injuries, Sarcoidosis, Ankylosing Spondylitis, Crystal-induced Arthritis

What Trends Are Influencing The Future Of The Arthralgia Market?

Leading companies in the arthralgia market are concentrating on creating novel therapies, including RMAT-designated gene therapy, to deliver advanced solutions for patients, aiming for lasting pain relief and better joint mobility. RMAT-designated gene therapy denotes a treatment granted the Regenerative Medicine Advanced Therapy (RMAT) designation by the FDA, a status that accelerates the development and regulatory review process for groundbreaking gene therapies addressing severe or life-threatening ailments. An example of this is when, in March 2024, Pacira BioSciences Inc., a US-based pharmaceutical firm, was awarded Regenerative Medicine Advanced Therapy (RMAT) designation by the U.S. Food and Drug Administration (FDA) for its product PCRX-201 (enekinragene inzadenovec). This particular candidate is an innovative, intra-articular gene therapy, employing a helper-dependent adenovirus (HDAd) for the treatment of knee osteoarthritis. The design of this therapy aims to produce interleukin-1 receptor antagonists (IL-1Ra). Pacira conveyed its pride in securing the FDA’s initial RMAT designation for an osteoarthritis-focused gene therapy and highlighted encouraging preliminary clinical outcomes, indicating that PCRX-201 could potentially be a disease-modifying treatment.

Which Companies Are Engaged In The Arthralgia Market Environment?

Major companies operating in the arthralgia market are Pfizer Inc., Johnson & Johnson Services Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline PLC, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Biogen Inc., UCB S.A., Hikma Pharmaceuticals PLC, Ferring Pharmaceuticals, KD Pharma Group S.A., SI-BONE Inc., Xalud Therapeutics Inc., Incannex Healthcare Limited, Cytonics Corporation

Access The Complete Arthralgia Market Report:

https://www.thebusinessresearchcompany.com/report/arthralgia-global-market-report

Which Area Represents The Largest Portion Of The Arthralgia Market?

North America was the largest region in the arthralgia market in 2025. The regions covered in the arthralgia market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Arthralgia Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=21104&type=smp

Browse Through More Reports Similar to the Global Arthralgia Market 2026, By The Business Research Company

Anthracite Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/anthracite-global-market-report

Artichokes Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/artichokes-global-market-report

Lenalidomide Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/lenalidomide-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795